Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Delphine Carmier"'
Autor:
Axelle Rivière, Anne Isabelle Lecuyer, Emeline Laurent, Carole Lefebvre, Thierry Lecomte, Elodie Olivier, Delphine Carmier, Laurent Plantier, Leslie Grammatico-Guillon
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Background It is unclear whether delays in care affect prognosis of patients with lung cancer. The primary objective of this study was to describe the care pathway of patients diagnosed with lung cancer in a French region. Secondary objectives were t
Externí odkaz:
https://doaj.org/article/6a93b7a3dce441c3a4e7d1994ec99287
Autor:
Xavier Cansouline, Béatrice Lipan, Damien Sizaret, Anne Tallet, Christophe Vandier, Delphine Carmier, Antoine Legras
Publikováno v:
Cancers, Vol 14, Iss 9, p 2257 (2022)
The ADAURA trial has been significant for the perception of EGFR tyrosine kinase inhibitors (TKIs) as a tool for early stage non-small-cell lung cancer (NSCLC). It produced such great insight that the main TKI, Osimertinib, was rapidly integrated int
Externí odkaz:
https://doaj.org/article/bd7ce7a15fdd49868681e2fccc988712
Autor:
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, Clarisse Audigier-Valette, Lionel Uwer, José Hureaux, Denis Moro-Sibilot, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto, Pierre-Jean Souquet, Valérie Gounant, Patrick Merle, Olivier Molinier, Aldo Renault, Audrey Rabeau, Franck Morin, Marc G Denis, Jean-Louis Pujol
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 12, p 3861 (2020)
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the
Externí odkaz:
https://doaj.org/article/858798049fc34b94b1313b6dc5af7b01
Autor:
Delphine Carmier, Catherine Dartigeas, Julie Mankikian, Cecilla Rousselot-Denis, Severine Lissandre, Patrice Diot, Sylvain Marchand-Adam
Publikováno v:
European Respiratory Review, Vol 22, Iss 129, Pp 416-419 (2013)
Externí odkaz:
https://doaj.org/article/f38528868ddb4375a97d318432b9a346
Autor:
Delphine Carmier, Catherine Dartigeas, Julie Mankikian, Cecilla Rousselot-Denis, Severine Lissandre, Patrice Diot, Sylvain Marchand-Adam
Publikováno v:
European Respiratory Review, Vol 22, Iss 130, Pp 589-589 (2013)
Externí odkaz:
https://doaj.org/article/9fb503cf655a4f359759214ad3a92ccb
Autor:
Valérie Gounant, Delphine Carmier, Alexandra Langlais, Lionel Uwer, Denis Moro-Sibilot, Franck Morin, Olivier Molinier, José Hureaux, Pierre-Jean Souquet, Patrick Merle, Jean-Louis Pujol, Sébastien Bommart, Clarisse Audigier-Valette, Pierre Mourlanette, Florian Guisier, Aldo Renault, Martine Antoine, Jeannick Madelaine, Laurent Greillier, Marc G. Denis, Audrey Rabeau, J. Otto
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2019, 14 (5), pp.903-913. ⟨10.1016/j.jtho.2019.01.008⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2019, 14 (5), pp.903-913. ⟨10.1016/j.jtho.2019.01.008⟩
Introduction This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line platinum–etoposide chemotherapy. Methods Patients were randomized 2:1 t
Autor:
Denis Moro-Sibilot, Guillaume Herbreteau, Olivier Molinier, José Hureaux, Patrick Merle, Jeannick Madelaine, Audrey Rabeau, J. Otto, Florian Guisier, Clarisse Audigier-Valette, Lionel Uwer, Valérie Gounant, Aldo Renault, Marc G. Denis, Laurent Greillier, Jean-Louis Pujol, Alexandra Langlais, Franck Morin, Pierre-Jean Souquet, Delphine Carmier
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, MDPI, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Journal of Clinical Medicine, Vol 9, Iss 3861, p 3861 (2020)
Journal of Clinical Medicine, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Volume 9
Issue 12
Journal of Clinical Medicine, MDPI, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Journal of Clinical Medicine, Vol 9, Iss 3861, p 3861 (2020)
Journal of Clinical Medicine, 2020, 9 (12), pp.3861. ⟨10.3390/jcm9123861⟩
Volume 9
Issue 12
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the
Autor:
Julien Mazieres, Pascal Do, Gérard Zalcman, O. Bylicki, Jacques Cadranel, Sylvie Lantuejoul, Franck Morin, Florian Guisier, Laurent Greillier, David Planchard, Olivier Molinier, Clarisse Audigier-Valette, Didier Debieuvre, Catherine Ligeza-poisson, M. Locatelli-Sanchez, Romain Corre, Delphine Carmier, Thierry Urban, Isabelle Monnet, Denis Moro-Sibilot, E. Amour, Arnaud Scherpereel, Sandrine Hiret, Séverine Fraboulet-Moreau
Publikováno v:
The Lancet Oncology
The Lancet Oncology, 2019, 20 (2), pp.239-253. ⟨10.1016/S1470-2045(18)30765-4⟩
The Lancet Oncology, 2019, 20 (2), pp.239-253. ⟨10.1016/S1470-2045(18)30765-4⟩
There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae99b54465162f6dcacf656787abcc08
https://hal.archives-ouvertes.fr/hal-02570690
https://hal.archives-ouvertes.fr/hal-02570690
Autor:
Stéphane Beltran, Louis Bernard, Helène Henique, Jacques Chandenier, Nicolas Drillaud, Marie-Alix De Kyvon, Philippe Corcia, Brigitte Chandenier, Delphine Carmier, Guillaume Desoubeaux
Publikováno v:
Clinical Infectious Diseases. 66:1637-1638
Publikováno v:
La Revue du praticien. 64(7)
After immunosuppressive-induced infections, interstitial lung disease (ILD) is one of the most serious pulmonary complications associated with connective tissue diseases (CTD). Although it is common for ILD to be diagnosed concurrent with or after CT